阅读说明：本技术 一种通过冷冻保存部分卵巢组织来延缓女性更年期的方法 (Method for delaying female menopause by freezing and preserving part of ovarian tissue ) 是由 鲁赫利亚达·尼科莱 茹孜古丽·阿布都外力 于 2020-05-29 设计创作，主要内容包括：本发明公开了一种通过冷冻保存部分卵巢组织来延缓女性更年期的方法,包括以下步骤：S1、通过腹腔镜手术取得在40-45岁的绝经前女性中部分卵巢的皮质和髓质层；S2、无菌条件下处置,以氙气装罐,将装罐的卵巢皮质和髓质层放入液氮内保存、冷冻；S3、当女性进入绝经期时,按标准阶段性取出冷冻保存的卵巢皮质和髓质层；S4、将取出的卵巢皮质和髓质层,在室温下解冻后,立即在无菌条件下机械压碎以形成细碎的悬浮液；S5、在围绝经期与绝经期采用激素疗法一起每2-4个月皮下植入一次；本发明通过以2-4个月的间隔皮下植入的卵巢移植组织使移植物连续起作用以产生足够的激素,移植技术和更年期激素疗法相结合达到最佳效果,通过这些特征的组合可以使女性在绝经期维持长期的卵巢功能,从而延长其预期寿命。(The invention discloses a method for delaying female menopause by cryopreservation of partial ovarian tissues, which comprises the following steps: s1, obtaining cortex and medulla layer of partial ovary in 40-45 year old premenopausal women through laparoscope operation; s2, treating under aseptic condition, canning with xenon, and storing and freezing the canned ovarian cortex and medulla layer in liquid nitrogen; s3, when the female enters the menopause, taking out the ovary cortex and medulla layer preserved by freezing according to standard stage; s4, mechanically crushing the removed ovarian cortex and medulla layer under aseptic conditions immediately after thawing at room temperature to form a finely divided suspension; s5, subcutaneously implanting the implant once every 2-4 months in peri-menopause and menopause by hormone therapy; the present invention enables the graft to continuously act by the ovary transplantation tissue implanted subcutaneously at intervals of 2-4 months to generate sufficient hormone, and the best effect is achieved by combining the transplantation technology and the climacteric hormone therapy, and the combination of the characteristics can enable the female to maintain the long-term ovary function in the menopause period, thereby prolonging the life expectancy thereof.)

1. A method for delaying menopause in women by cryopreserving a portion of ovarian tissue, comprising the steps of:

s1, obtaining cortex and medulla layer of partial ovary in 40-45 year old premenopausal women through laparoscope operation;

s2, treating under aseptic condition, canning with xenon, and storing and freezing the canned ovarian cortex and medulla layer in liquid nitrogen;

s3, when the female enters the menopause, taking out the ovary cortex and medulla layer preserved by freezing according to standard stage;

s4, mechanically crushing the removed ovarian cortex and medulla layer under aseptic conditions immediately after thawing at room temperature to form a finely divided suspension;

s5, subcutaneously every 2-4 months during peri-and menopause using hormonal therapy.

2. A method of delaying menopause in women by cryopreservation of a portion of ovarian tissue as claimed in claim 1 wherein: in S1, when the cortex and medullary layer of partial ovary of female is removed, the physical condition of female with partial ovary tissue to be removed is determined, the normal menstrual cycle of female to be removed is not interfered, the anti-mullerian hormone level is not lower than 1.5-0.8ng/ml, the follicle stimulating hormone level is not higher than 25mU/l, and meanwhile, when the female with partial ovary tissue to be removed is determined to be in the non-menopausal period, the cortex and medullary layer should be removed equally when the ovary fragments are removed, and the wedge-shaped removal is preferred.

3. A method of delaying menopause in women by cryopreservation of a portion of ovarian tissue as claimed in claim 1 wherein: at S2, when handling under aseptic conditions, canning with xenon, and freezing the canned ovarian cortex and medullary layer in liquid nitrogen, the method comprises the following steps:

s21, under aseptic conditions, immediately cutting the mixture into strips or strips: the length of the whole ovary is 8-10mm, and the section does not exceed 2x2 mm;

s22, putting the strips into a sealed capsule filled with xenon at the pressure of 1.5 standard atmospheric pressure, and gradually cooling to 0 ℃ at the rate of 1 ℃ per minute;

s23, after the exposure is carried out for 60-62 minutes at the zero temperature, the cooling is continued to be carried out to-20 ℃ at the rate of 1 ℃ per minute;

s24, immediately after cooling to-20 degrees celsius, the capsules were transferred to liquid nitrogen where they were stored for an indefinite period of time.

4. A method of delaying menopause in women by cryopreservation of a portion of ovarian tissue as claimed in claim 3 wherein: the freezing time of the canned ovarian cortex and medullary layer is not less than three years, and the preservation time is recorded when the canned ovarian cortex and medullary layer is preserved.

5. A method of delaying menopause in women by cryopreservation of a portion of ovarian tissue as claimed in claim 3 wherein: in S4, when the removed ovarian cortex and medullary layer are prepared as a fine suspension, the method comprises the following steps:

after thawing at room temperature, when one or more capsules are opened, the ovarian tissue is immediately mechanically comminuted under sterile conditions until fine fragments are obtained, which can be pressed through a syringe needle having a lumen diameter of 2mm, with a tissue volume of 3-4 cubic millimeters for a single implantation.

6. A method of delaying menopause in women by cryopreservation of a portion of ovarian tissue as claimed in claim 1 wherein: the removed part of the ovarian cortex and medulla layer is 25-30% of the ovarian cortex and medulla layer on each side.

7. A method of delaying menopause in women by cryopreservation of a portion of ovarian tissue as claimed in claim 1 wherein: when a woman who has removed a part of ovarian tissue enters the peri-menopause period, menopause hormone treatment is started and taken together with a preparation containing estradiol, and a small fragment suspension made of thawed ovarian fragments containing medullary and cortical substances is periodically administered to the woman who has removed a part of ovarian tissue for subcutaneous implantation.

8. A method of delaying menopause in women by cryopreservation of a portion of ovarian tissue as claimed in claim 7 wherein: the interval time of the subcutaneous implantation of the female small fragment suspension of which part of the ovarian tissues are taken out is 2-4 months, and the suspension is matched with the climacteric hormone drug replacement therapy.

Technical Field

The invention belongs to the field of medicine, particularly relates to the field of gynecology, endocrinology and geriatric medicine, and particularly relates to a method for delaying female menopause by freezing and preserving part of ovarian tissues.

Background

Ovary, anatomical name. Located in the female pelvic cavity, are paired parenchymal organs. Its main functions are to produce and discharge egg cells, and to secrete sex hormones to promote and maintain the development of female sexual characteristics.

Perimenopausal syndrome, also known as climacteric syndrome (MPS), refers to a group of syndromes caused by sex hormone fluctuation or decrease before and after menopause of women, mainly dysfunction of autonomic nervous system, accompanied with neuropsychological symptoms. Menopause can be divided into natural menopause and artificial menopause. Natural menopause refers to the menopause resulting from the exhaustion of follicles in the ovary, or the loss of responsiveness of the remaining follicles to gonadotropins, the failure of the follicles to develop and secrete estrogen, and the inability to stimulate endometrial growth. Artificial menopause refers to surgical removal of bilateral ovaries or other methods of stopping ovarian function, such as radiation therapy and chemotherapy. Those with resected uterus alone, with one or both ovaries remaining, do not act as artificial menopause.

Along with the rapid development of society, people pay more and more attention to the maintenance of bodies, wherein for female population, the coming of female climacteric with the age deeply affects the normal life of women, the serious person is called climacteric syndrome, nowadays, the delaying method of female climacteric has a plurality of delaying methods, and some delaying methods adopt medicines, such as Chinese published and authorized to invent a pharmaceutical composition (publication No. CN200710302041.6) for treating female climacteric syndrome and delaying senility, mainly tonifying kidney with traditional Chinese medicines, and is used for female climacteric, and the Chinese patent medicine is characterized by having the obvious effects of homology of medicine and food, preventing and treating synchronization and pure Chinese herbal compound, improving the health quality of female climacteric, improving female climacteric syndrome, osteoporosis, improving immune function, resisting aging and improving cardiovascular function, however, because the physical conditions of everyone are different, some people can generate rejection reaction to one of the medicines, the effect of delaying the menopause of the people is not good, and meanwhile, other people can reject the medicine treatment, so the invention has larger limitation, and other female climacteric patients can delay the menopause by using the ovarian tissue autotransplantation method, but the method adopts the ovary of her people to cause moral and legal problems, so the method for delaying the menopause of the women by freezing and storing part of the ovarian tissue is provided.

Disclosure of Invention

The present invention aims to solve the problems of the background art mentioned above by providing a method for delaying the menopause of women by cryopreservation of a part of ovarian tissue.

In order to achieve the purpose, the invention adopts the following technical scheme:

a method for delaying menopause in women by cryopreserving a portion of ovarian tissue, comprising the steps of:

s1, obtaining cortex and medulla layer of partial ovary in 40-45 year old premenopausal women through laparoscope operation;

s2, treating under aseptic condition, canning with xenon, and storing and freezing the canned ovarian cortex and medulla layer in liquid nitrogen;

s3, when the female enters the menopause, taking out the ovary cortex and medulla layer preserved by freezing according to standard stage;

s4, mechanically crushing the removed ovarian cortex and medulla layer under aseptic conditions immediately after thawing at room temperature to form a finely divided suspension;

s5, subcutaneously every 2-4 months during peri-and menopause using hormonal therapy.

Preferably: in S1, when the cortex and medullary layer of partial ovary of female is removed, the physical condition of female with partial ovary tissue to be removed is determined, the normal menstrual cycle of female to be removed is not interfered, the anti-mullerian hormone level is not lower than 1.5-0.8ng/ml, the follicle stimulating hormone level is not higher than 25mU/l, and meanwhile, when the female with partial ovary tissue to be removed is determined to be in the non-menopausal period, the cortex and medullary layer should be removed equally when the ovary fragments are removed, and the wedge-shaped removal is preferred.

Preferably: at S2, when handling under aseptic conditions, canning with xenon, and freezing the canned ovarian cortex and medullary layer in liquid nitrogen, the method comprises the following steps:

s21, under aseptic conditions, immediately cutting the mixture into strips or strips: the length of the whole ovary is 8-10mm, and the section does not exceed 2x2 mm;

s22, putting the strips into a sealed capsule filled with xenon at the pressure of 1.5 standard atmospheric pressure, and gradually cooling to 0 ℃ at the rate of 1 ℃ per minute;

s23, after the exposure is carried out for 60-62 minutes at the zero temperature, the cooling is continued to be carried out to-20 ℃ at the rate of 1 ℃ per minute;

s24, immediately after cooling to-20 degrees celsius, the capsules were transferred to liquid nitrogen where they were stored for an indefinite period of time.

Preferably: the freezing time of the canned ovarian cortex and medullary layer is not less than three years, and the preservation time is recorded when the canned ovarian cortex and medullary layer is preserved.

Preferably: in S4, when the removed ovarian cortex and medullary layer are prepared as a fine suspension, the method comprises the following steps:

after thawing at room temperature, when one or more capsules are opened, the ovarian tissue is immediately mechanically comminuted under sterile conditions until fine fragments are obtained, which can be pressed through a syringe needle having a lumen diameter of 2mm, with a tissue volume of 3-4 cubic millimeters for a single implantation.

Preferably: the removed part of the ovarian cortex and medulla layer is 25-30% of the ovarian cortex and medulla layer on each side.

Preferably: when a woman who has removed a part of ovarian tissue enters the peri-menopause period, menopause hormone treatment is started and taken together with a preparation containing estradiol, and a small fragment suspension made of thawed ovarian fragments containing medullary and cortical substances is periodically administered to the woman who has removed a part of ovarian tissue for subcutaneous implantation.

Preferably: the interval time of the subcutaneous implantation of the female small fragment suspension of which part of the ovarian tissues are taken out is 2-4 months, and the suspension is matched with the climacteric hormone drug replacement therapy.

The invention has the technical effects and advantages that: compared with the prior art, the method for delaying the female menopause by cryopreservation of part of ovarian tissues provided by the invention has the following advantages:

in the method of the present invention, the ovarian tissue is autotransplanted, which eliminates the possibility of rejection of the recipient transplant and also eliminates many moral and legal problems associated with tissue and organ allografts, and at the same time, because the ovarian transplantation is performed from the transplant itself, the method of the present invention is not limited, and only needs to be performed by each woman before entering the menopause;

taking and storing the autograft before menopause can store still active ovarian tissues and ensure that especially a medullary layer is responsible for inhibiting apoptosis and tissue survival in the storage process;

cryopreservation of ovarian tissue using liquid nitrogen bottled in xenon gas allows for reimplantation ("return") after an indefinite time;

fourthly, by storing the ovarian graft in a separate capsule, the fragments can be gradually thawed for transplantation; the entire volume of tissue need not be thawed for implantation.

The invention enables the transplant to continuously act to generate enough hormone by the ovary transplantation tissue implanted subcutaneously at intervals of 2-4 months, the best effect is achieved by combining the transplantation technology and the climacteric hormone therapy, and the combination of the characteristics can enable the female to maintain the long-term ovary function in the menopause period, thereby prolonging the life expectancy of the female.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. The specific embodiments described herein are merely illustrative of the invention and do not delimit the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.